Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
The DOI matches its Crossref record; 217 of the 218 references it cites were found in a registry or an index.
Abstract
The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel glucagon-like peptide-1 (GLP-1)-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-entero-pancreatic hormones such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY to enhance energy uptake, storage, and expenditure through synergistic mechanisms. Both GIP receptor agonism and antagonism, particularly in combination with GLP-1 receptor agonism, have shown promise. Maridebart cafraglutide, combining GLP-1 receptor agonism with GIP receptor antagonism, exemplifies this innovative approach. Glucagon coagonists like survodutide and mazdutide have demonstrated significant weight loss and improved glycemic control. Amylin-based agents, including CagriSema (cagrilintide + semaglutide) and amycretin, enhance satiety and glycemic outcomes through complementary actions. Further innovation is seen in triple agonists such as retatrutide, which targets GIP, GLP-1, and glucagon receptors to amplify metabolic effects. Meanwhile, the emergence of orally active small-molecule GLP-1 receptor agonists like danuglipron and orforglipron, which are resistant to enzymatic degradation, marks a major advance in patient-friendly drug delivery. This review explores the mechanisms, clinical development, and therapeutic potential of these novel agents, excluding already approved drugs like liraglutide, semaglutide, and tirzepatide. We highlight how multireceptor agonists and oral GLP-1-based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
Cited work 10.3831/kpi.2017.20.029 · retracted 2020-03-31 · notice 10.3831/kpi.2020.23.007 · this paper published 2025-10-07
Citations
Cites
1 retracted
A Review on the Role of Irisin in Insulin Resistance and Type 2 Diabetes Mellitus.
Gizaw, M., Anandakumar, P., & Tolessa, D. (2017) · PubMed · doi:10.3831/kpi.2017.20.029 · Cited by 68
RetractedLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
(2020) · PubMed · Cited by 2,642
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Cited by
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies
Alhazmi, A., & le Roux, C. W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1788698 · Cited by 10
Self-citationLempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
“Multi-receptor agonists combining GLP-1 with glucose-dependent insulinotropic polypeptide (GIP), glucagon, or amylin demonstrate enhanced weight loss and metabolic benefits through synergistic mechanisms that augment energy expenditure, lipolysis, and satiety beyond GLP-1 alone [39].”
The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population
Accacha, S. D., Barillas, J., Gabriel, L., Srivastava, A., Gulkarov, S., Apsan, J., Leon, J. D., & Reiss, A. B. (2026) · Biomedicines · doi:10.3390/biomedicines14010198 · Cited by 4
“Their use can be an effective strategy in improving overall glycemic control [208–210].”
Current Knowledge of Obesity‐Related Vascular Injury
Liu, J., & Yang, D. (2025) · Obesity Reviews · doi:10.1111/obr.70080 · Cited by 5
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Glucagon-like peptide-1 receptor agonists and hair loss: Current evidence and potential mechanisms
Spindler, A. J., Maas, D., Rachko, G., Zappi, I., Kapur, S. K., Sidhu, K. S., Maas, K., Garza-García, L. M., Patrocínio, J., Petukhova, L., et al. (2026) · JAAD reviews. · doi:10.1016/j.jdrv.2026.07.002 · Cited by 2
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
“The therapeutic landscape for metabolic diseases—encompassing type 2 diabetes mellitus (T2DM), obesity, and their cardiovascular sequelae—has been fundamentally transformed by the widespread adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) [1,2].”
Rega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
“For example, activation of GLP-1 and amylin receptors in the hindbrain and hypothalamus modulates sympathetic and parasympathetic tone, thereby affecting hepatic glucose production, adipose tissue lipolysis, and skeletal muscle oxidative capacity [239,240].”
Alhazmi, A., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71074 · Cited by 1
“The therapeutic landscape of obesity pharmacotherapy has evolved substantially over the past decades, progressing from traditional oral agents such as orlistat and phentermine/topiramate to the transformative era of glucagon-like peptide-1 receptor agonists (GLP-1RAs) [1–4].”
Self-citationLee, S.-H. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70349 · Cited by 1
Chen, Q., Chen, T., Lin, W., & Chen, X. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s585436 · Cited by 3
Recent developments in GPCR signalling in appetite regulation
Brittain, H. R., & Gorvin, C. M. (2026) · Bioscience Reports · doi:10.1042/bsr20250120 · Cited by 1
Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review
van Maren, S., van Doorn, E. P. M., Smits, M. M., Tack, C. J., van Rossum, E. F. C., & Messaoudi, S. E. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02073-3 · Cited by 1
“…multi-receptor agonists targeting pathways such as GLP-1, GIP, glucagon, and amylin are currently under development and are expected to produce even greater effects on body weight; their potential impact on cardiovascular outcomes will therefore be an important area of future investigation [62].”
Cardiovascular–Kidney–Metabolic (CKM) Syndrome Staging and Relevance to Precision Nutrition
Soliman, G. A. (2026) · Nutrients · doi:10.3390/nu18091430 · Cited by 2
“In addition, it reduces appetite and slows gastric emptying, thereby reducing body weight and obesity [101].”
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040447 · Cited by 1
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Accuracy of Water Intake During Simulated Administration of Oral Semaglutide
Ketaroonrut, N., Jantarapootirat, M., Traiwanatham, S., Katekao, P., & Sriphrapradang, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71395
Optimizing timing of exercise to improve metabolic outcomes in obesity and type 2 diabetes
Kotte, M., Hoeks, J., Schrauwen, P., & van de Weijer, T. (2026) · npj Biological Timing and Sleep · doi:10.1038/s44323-026-00099-9
“Given the rise in use of GLP-1 receptor agonists for the treatment of obesity and type 2 diabetes 44 , future studies should carefully consider medication use and how this may interact with timing of exercise.”
Mitochondrial remodeling as a effector of glp-1 therapy in obesity and diabetes: review
Alhindi, Y. Z. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/bfye5lnqza
Future GLP-1 receptor co-agonists and their cardiac effects
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05908-3
Geddam, R., Kamatham, S., & Ashok, C. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100721 · Cited by 1
Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., Salles, O. J. D. M., & de Oliveira, L. M. (2026) · Research Square · doi:10.21203/rs.3.rs-9783878/v1
Alam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_17_26
Zhang, C., Wang, Z. M., Jiang, Z.-J., Kim, H., Liu, C., & Wang, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1838267 · Cited by 2
“…chronic administration over 4 weeks translated this acute secretory boost into sustained metabolic benefits, including attenuated weight gain and food intake, improved glucose tolerance, and enhanced insulin sensitivity, which were consistent with the effects of elevated GLP-1 (Son et al., 2025).”
Ji, L., Chen, L., Cheng, Z., Lu, Y., Yang, Y., Fu, F., Zhu, Y., Jin, L., & Kloer, I. M. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01908-x
“…orfor-glipron), GLP-1 and amylin receptor dual agonist (e.g., CagriSema, amycretin), GLP-1 and GIP receptor dual agonists (e.g., HRS9531), GLP-1 and GCG receptor dual agonists (e.g., survodu-tide, pemvidutide), and GLP-1, GIP, and GCG receptor triple agonists (e.g., retatrutide) [13, 23, 30, 31].”
Hayat, I., Sattar, T., Shafiq, S., Ejaz, H. M., & Noor, M. H. (2025) · Developmental medico-life-sciences · doi:10.69750/dmls.02.010.0168
“Injury-site reactions were only seen in some patients, but they did not affect the treatment adherence and tolerability [19,20].”
From stomach to striatum: Ghrelin infusions increase work for rewardsPreprint
Schulz, C., Peglow, F., la Fougère, C., Bender, B., Klaus, J., Ellinger, S., Walter, M., Reischl, G., Reimold, M., & Kroemer, N. B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.04.691596
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01921-0
Lai, W., Peng, L., Min, J., Qiu, L., Wang, C., Yu, S., Li, Q., Li, R., Jiang, X., & Chen, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1665860
Metabolic advances in 2025: from clinical breakthroughs to molecular reprogramming
Dalamaga, Μ., & Liu, J. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100442 · Cited by 2
“The trials indicate a shift toward combination pharmacotherapy in metabolic disease, as the magnitude of benefit with CagriSema approaches or exceeds that of dual and triple agonists such as tirzepatide and retatrutide [6].”
Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine
Guo, J., & Chen, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1933018
“Orforglipron (LY3502970; Eli Lilly; Foundayo), danuglipron (PF-06882961; Pfizer), and the discontinued lotiglipron (PF-07081532) represent the vanguard of this new class (Son et al., 2026).”
Alam, A., & Salman, M. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_31_26
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
Metadata
- Authors
- Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S.
- Affiliations
- The Catholic University of Korea Bucheon St. Mary's Hospital (KR)
- University College Dublin (IE)
- Helmholtz Munich (DE)
- St. Josef-Hospital (DE)
- Seoul National University (KR)
- Corresponding author
- Nauck, Michael A
- Lim, Soo
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2025-10-07
- Volume
- 47
- Issue
- 2
- Pages
- 159-177
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W4414917129
- Semantic Scholar
- d9402dc1978bdb4910ddb479ab4625eee7177431
- Cited by
- 40
- References
- 209
- Citations by year
- 2026: 36 · 2025: 4
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, glucagon receptor agonist, amylin receptor agonist, peptide YY, survodutide, mazdutide, cagrilintide, retatrutide, orforglipron, oral GLP-1 receptor agonists, weight loss, glycemic control
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.